MagNeo: Delayed SLND for Patients With Breast Cancer Undergoing Primary Systemic Treatment

Sponsor

Uppsala University (Other)

Overall Status

Active, not recruiting

CT.gov ID

NCT05985551

Collaborator

Uppsala University Hospital (Other)

114

Enrollment

Location

45.9

Anticipated Duration (Months)

2.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The goal of this study was to assess the feasibility of SLND by superparamagnetic iron oxide nanoparticles (SPIO) in patients with early breast cancer planned for primary systemic therapy (PST) and whether this is affected by the timeframe of SPIO administration.

For this, patients with cN0/1 disease planned for PST received radioisotope as per routine on the day of surgery or the day before, and SPIO was injected in an extended timeframe, at any point from the day of surgery to before the induction of PST.

The main points to investigate are:

If the SPIO detection rate and concordance to the radiosotope are affected by time of SPIO injection
If the nodal yield and the accuracy of the procedure are affected

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer Chemotherapy Effect Sentinel Lymph Node	Other: SLND or TAD by the magnetic technique (SPIO)

Detailed Description

Superparamagnetic Iron Nanoparticles (SPIO) have shown comparable performance to the standard of Radioisotope (RI) +/- blue dye (BD) for Sentinel Lymph Node Detection in breast cancer, with the advantage of clinical convenience due to easier accessibility, disposal and injection days before surgery.

More interestingly, SPIO provides the possibility for delayed SLND in the setting of a preoperative diagnosis of DCIS, enabling SLN detection weeks after breast surgery, only when specimen pathology has demonstrated invasive cancer, as shown in the SentiNot study. The role of SPIO for SLND in the setting of primary systemic therapy (PST) has not been extensively investigated, while the timeframe from SPIO administration to successful SLN detection in a similar fashion to SentiNot, but in the setting of PST has yet to been defined.

Current evidence suggest that RI-based SLN detection is the accepted standard following PST, with RI-based dual mapping specifically recommended in cN+-to-ycN0 patients, when SLND or targeted axillary dissection (TAD) are performed, as the number of SLNs retrieved has been inversely linked to the false negative rate of the procedure.

Apart from the logistic benefits of SPIO administration prior to PST, an aspect of potential interest is the ability to map the axilla, before the fibrotic changes induced by chemotherapy and lymphatic remodelling occur, that are a concern, especially in the node-positive patients at presentation.

However, in this case, it is imperative to investigate that SPIO remains detectable after a prolonged period of administration and that it does not migrate to higher nodal echelons. While preliminary data suggested feasibility, the aim of this dedicated study was to investigate the width of timeframe of SPIO administration in patients undergoing PST and how SPIO-based detection and concordance to the RI are affected.

In this study, patients scheduled for SLND or TAD after surgery will undergo the procedure with RI as the standard of care and will moreover receive SPIO. The administration of SPIO will take place either on the preoperative period but after the completion of PST, or before the induction of PST. The reason for this is to create a wide time-frame to allow for conclusion with regards to whether the mapping of the axilla prior PST by SPIO is a feasible technique that will then be addressed in a dedicated trial.

Study Design

Study Type:

Observational

Anticipated Enrollment :

114 participants

Observational Model:

Other

Time Perspective:

Prospective

Official Title:

A Feasibility Study on the Timeframe of Superparamagnetic Iron Oxide Nanoparticles Administration in Patients Receiving Primary Systemic Therapy for Early Breast Cancer

Actual Study Start Date :

Jan 1, 2020

Actual Primary Completion Date :

Oct 30, 2022

Anticipated Study Completion Date :

Oct 30, 2023

Outcome Measures

Primary Outcome Measures

Correlation between concordance (isotope and SPIO) and timepoint of SPIO administration to surgery [At surgery]
This endpoint is necessary in ensuring that prolonged SPIO administration does not result in the retrieval of "false" SLNs, in the case that SPIO migrates to higher nodal echelons. As the radioisotope is the current standard of care, the concordance of SPIO to the radioisotope and its correlation with time of SPIO adminstration is the appropriate surrogate endpoint.
Detection rate [At surgery]
The successful retrieval of at least one SLN detected by each tracer (SPIO or radioisotope) separately.
Concordance [At surgery]
The rate (patients with at least one SLN detected with both tracers/patients with at least one SLN detected with the radioisotope)

Secondary Outcome Measures

Nodal yield [At surgery]
The median number of SLNs retrieved with each tracer
Nodal concordance [At surgery]
The rate (SLNs detected by both tracers/SLNs detected by the radioisotope)

Other Outcome Measures

Detection rate for 2 and 3 SLNs [At surgery]
The successful retrieval of at least two and at least three SLN detected by each tracer (SPIO or radioisotope) separately.
Adverse events [From time of SPIO administration to four weeks after surgery]
Any adverse events reported in relation to SPIO administration

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Adult patients with non-metastatic primary breast cancer and cN0/cN1 axilla, as defined by clinical examination and axillary ultrasound (with fine needle aspiration or core biopsy verification of metastasis) intended for PST (chemotherapy, targeted treatment or endocrine therapy) with a curative intention at diagnosis,

Exclusion Criteria:

Distant metastases at diagnosis
Inflammatory breast cancer
Tumor progression during PST for cN1 patients
ycN1 after completion of PST
surgery before the completion of PST for any reason (PST adverse effects, patient preference)
cN1-to-ycN0 patients that opted for ALND